Fresh2 Group マネジメント

マネジメント基準チェック /04

Fresh2 Groupの CEO はHaohan Xuで、 May2023年に任命され、の在任期間は 1.5年です。は、会社の株式の15.7%を直接所有しており、その価値は$ 441.85K 。経営陣と取締役会の平均在任期間はそれぞれ1.5年と2.1年です。

主要情報

Haohan Xu

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.5yrs
CEOの所有権	15.7%
経営陣の平均在職期間	1.5yrs
取締役会の平均在任期間	2.1yrs

経営陣の近況

Recent updates

AnPac Bio announces plan to implement ADS ratio change

Oct 18

AnPac Bio-Medical Science announces management changes

Oct 03

AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group

Sep 27

AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases

Dec 14

Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%

Dec 11

AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%

Nov 25

AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%

Nov 02

CEO（最高経営責任者

Haohan Xu (29 yo)

1.5yrs

在職期間

Mr. Haohan Xu serves as Chief Executive Officer at Fresh2 Group Limited since May 17, 2023. He served as Co-Chief Executive Officer of Fresh2 Group Limited until May 17, 2023 and serves as its Chairman of...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Haohan Xu	Chairman of the Board & CEO	1.5yrs	データなし	15.7% $ 441.8k
Xiaoyu Li	Director & CFO	1.3yrs	データなし	データなし
Weidong Dai	China President	9.6yrs	データなし	データなし
Sunil Pandit	U.S. Chief Executive Officer	3.3yrs	データなし	データなし
Yidong Hu	Chief Strategy Officer	1.3yrs	データなし	データなし

1.5yrs

平均在職期間

35yo

平均年齢

経験豊富な経営陣: FRESの経営陣は経験豊富とはみなされません ( 1.5年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Haohan Xu	Chairman of the Board & CEO	2.1yrs	データなし	15.7% $ 441.8k
Xiaoyu Li	Director & CFO	2.1yrs	データなし	データなし
Lee Shulman	Member of Technical Advisory Board	6.1yrs	データなし	データなし
Tianruo Pu	Independent Director	2.1yrs	データなし	データなし
Honggang Tian	Independent Director	2.1yrs	データなし	データなし
Zhigang Zhao	Independent Director	2.1yrs	データなし	データなし
Zhijun Liang	Independent Director	less than a year	データなし	データなし
Xiaohui Zhang	Independent Director	no data	データなし	データなし

2.1yrs

平均在職期間

43yo

平均年齢

経験豊富なボード: FRESの取締役会は経験豊富ではない ( 2.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Fresh2 Group マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

High number of new and inexperienced directors

Fresh2 Group Limited Appoints Zhijun (Michael) Liang as Independent Director, Effective January 1, 2024

Fresh2 Group Limited Appoints Yidong Hu as Chief Strategy Officer

Fresh2 Group Limited Announces the Resignation of Chris Chang Yu as Co-Chief Executive Officer

AnPac Bio-Medical Science Co., Ltd. Announces Board Resignations

Anpac Bio-Medical Science Co., Ltd. Appoints Xiaoyu Li as Chief Financial Officer

Recent updates

New major risk - Financial data availability

High number of new and inexperienced directors

Fresh2 Group Limited Announces Receipt of A Delinquency Compliance Alert Notice from Nasdaq

Fresh2 Group Limited announced delayed annual 10-K filing

Fresh2 Group Ltd Launches TikTok Video E-commerce Venture, Bridging the Gap Between Food Sources and Consumers

Fresh2 Group Receives Deficiency Notice from the Nasdaq Regarding Fails to Comply with the $1 Minimum Bid Price Required for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Fresh2 Group Limited Appoints Zhijun (Michael) Liang as Independent Director, Effective January 1, 2024

Ningkasai Technology (Shanghai) Co., Ltd. entered into a share purchase agreement to acquire Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. from Fresh2 Group Limited (NasdaqCM:FRES) for CNY 1.

Fresh2 Group Limited (NasdaqCM:FRES) acquired Roxe Holding Inc.

Fresh2 Group Limited Appoints Yidong Hu as Chief Strategy Officer

Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing Requirements

Fresh2 Group Limited Announces the Resignation of Chris Chang Yu as Co-Chief Executive Officer

AnPac Bio-Medical Science Co., Ltd. (NasdaqCM:ANPC) entered into an agreement to acquire Fresh2 Ecommerce Inc for $2.1 million.

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $5 million in funding

AnPac Bio-Medical Science Announces Regaining Compliance with Nasdaq Listing Requirement

AnPac Bio-Medical Science Co., Ltd. Announces Board Resignations

AnPac Bio Granted Continued Listing by Nasdaq Hearing Panel

AnPac Bio announces plan to implement ADS ratio change

Anpac Bio-Medical Science Co., Ltd. Appoints Xiaoyu Li as Chief Financial Officer

AnPac Bio-Medical Science announces management changes

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $3.67 million in funding

AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group

AnPac Bio-Medical Science Appeals Nasdaq Delisting Notice; Hearing Granted and Scheduled for October 20, 2022

AnPac Bio-Medical Science Co., Ltd. Appeals Nasdaq Delisting Notice

Less than half of directors are independent

AnPac Bio-Medical Science Co., Ltd. Announces Executive Appointments

AnPac Bio appoints Yuyang Cui as co-chief executive officer

AnPac Bio-Medical Science Co., Ltd. Approves CEO Changes

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $1.5 million in funding

Anpac Bio-Medical Science Co., Ltd. Appoints Chris Chang Yu as Co-CEO of the Company

AnPac Bio-Medical Science Co., Ltd. announced delayed 20-F filing

High number of new directors

AnPac Bio-Medical Science Co., Ltd. Announces Executive Changes

AnPac Bio-Medical Science Announces Receipt of Staff Delisting Determination from Nasdaq

AnPac Bio-Medical Science Co., Ltd. Files CDA Device for Breakthrough Medical Device Designation Request with the FDA

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in first quarter of 2022

Third quarter 2021 earnings: Revenues miss analyst expectations

Second quarter 2021 earnings released: CN¥2.16 loss per share (vs CN¥3.15 loss in 2Q 2020)

AnPac Bio-Medical Science Co., Ltd. Completes Major Preclinical Study, Files with National Medical Products Administration for Registration Testing of Its Multi-Cancer CDA Device

AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds

AnPac Bio stock soars 15% after securing first disease treatment patent in U.S.

Consensus revenue estimates fall to CN¥34.5m

First quarter 2021 earnings released: CN¥1.93 loss per share (vs CN¥2.56 loss in 1Q 2020)

AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database

Full year 2020 earnings released

New 90-day high: US$7.70

NMPA Approves Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)

AnPac Bio wins new US patent for multi-cancer detection

AnPac Bio-Medical Science Co., Ltd. Makes Significant Progress in Detecting Pre-Cancer Diseases and Recorded over 20 Types of Pre-Cancer Diseases

AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases

Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%

New 90-day high: US$7.14

AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%

Anpac Bio-Medical Science Co., Ltd. Appoints Jianhua Shao as Independent Director and Member of Compensation Committee

AnPac Bio-Medical Science Co., Ltd. Completes COVID-19 Antibody Test Verification

AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%

New 90-day low: US$3.38

New 90-day low: US$4.20

First half earnings released

New 90-day low - US$4.80

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04